Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice

[Image: see text] The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid, and molnupiravir), or in advanced clinical trials. Vandetanib is a kinase inhibitor which targets the...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhl, Ana C., Gomes, Giovanni F., Damasceno, Samara, Fritch, Ethan J., Levi, James A., Johnson, Nicole J., Scholle, Frank, Premkumar, Lakshmanane, Hurst, Brett L., Lee-Montiel, Felipe, Veras, Flavio P., Batah, Sabrina S., Fabro, Alexandre T., Moorman, Nathaniel J., Yount, Boyd L., Dickmander, Rebekah J., Baric, Ralph S., Pearce, Kenneth H., Cunha, Fernando Q., Alves-Filho, José C., Cunha, Thiago M., Ekins, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454268/
https://www.ncbi.nlm.nih.gov/pubmed/36097511
http://dx.doi.org/10.1021/acsomega.2c02794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454268/
https://www.ncbi.nlm.nih.gov/pubmed/36097511
http://dx.doi.org/10.1021/acsomega.2c02794

Ejemplares similares